A long non-coding RNA snaR contributes to 5-fluorouracil resistance in human colon cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Drug resistance is a major challenge in cancer therapy, with genetic and epigenetic factors playing key roles.
• Non-coding RNAs, including long non-coding RNAs (lncRNAs), are increasingly recognized for their involvement in drug resistance mechanisms.
• The specific lncRNAs and their functions in 5-fluorouracil (5-FU) resistance in colon cancer require further elucidation.

Purpose of the Study:

• To identify differentially expressed lncRNAs in 5-fluorouracil-resistant colon cancer cells.
• To investigate the functional role of specific lncRNAs, such as snaR, in mediating 5-FU resistance.
• To provide insights into the contribution of lncRNAs to the development of colon cancer drug resistance.

Main Methods:

• Quantitative real-time PCR (qPCR)-based profiling was used to analyze the expression of 90 lncRNAs.
• Two pairs of 5-FU-resistant colon cancer cell lines (SNU-C4R and SNU-C5R) were utilized.
• Small interfering RNAs (siRNAs) targeting snaR were transfected to assess its effects on cell viability, death, and cell cycle.

Main Results:

• Nineteen and twenty-three lncRNAs were found to be differentially expressed in SNU-C4R and SNU-C5R cells, respectively.
• The lncRNAs snaR and BACE1AS were confirmed to be downregulated in the resistant cell lines.
• Downregulation of snaR led to decreased cell death upon 5-FU treatment, indicating reduced in vitro sensitivity to 5-FU.

Conclusions:

• lncRNAs are significantly involved in the development of 5-FU resistance in colon cancer.
• The lncRNA snaR plays a crucial role in modulating sensitivity to 5-FU chemotherapy.
• Targeting specific lncRNAs like snaR may represent a potential strategy to overcome drug resistance in colon cancer therapy.